AbbVie Inc. (4AB.DE)
EUR 173.2
(2.24%)
EUR 173.2
(2.24%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | 4.86 Billion USD | -58.91% |
| 2022 | 11.83 Billion USD | 2.55% |
| 2021 | 11.54 Billion USD | 150.04% |
| 2020 | 4.61 Billion USD | -41.44% |
| 2019 | 7.88 Billion USD | 38.6% |
| 2018 | 5.68 Billion USD | 7.12% |
| 2017 | 5.3 Billion USD | -10.82% |
| 2016 | 5.95 Billion USD | 15.73% |
| 2015 | 5.14 Billion USD | 189.97% |
| 2014 | 1.77 Billion USD | -57.03% |
| 2013 | 4.12 Billion USD | -21.74% |
| 2012 | 5.27 Billion USD | 53.65% |
| 2011 | 3.43 Billion USD | -17.83% |
| 2010 | 4.17 Billion USD | -9.89% |
| 2009 | 4.63 Billion USD | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q2 | 1.37 Billion USD | 0.07% |
| 2024 Q1 | 1.36 Billion USD | 66.55% |
| 2023 Q2 | 2.02 Billion USD | 746.86% |
| 2023 Q4 | 822 Million USD | -53.77% |
| 2023 FY | 4.86 Billion USD | -58.91% |
| 2023 Q3 | 1.77 Billion USD | -12.15% |
| 2023 Q1 | 239 Million USD | -90.34% |
| 2022 FY | 11.83 Billion USD | 2.55% |
| 2022 Q4 | 2.47 Billion USD | -37.09% |
| 2022 Q3 | 3.93 Billion USD | 330.56% |
| 2022 Q2 | 913 Million USD | -79.57% |
| 2022 Q1 | 4.46 Billion USD | 11.06% |
| 2021 Q2 | 749 Million USD | -78.78% |
| 2021 FY | 11.54 Billion USD | 150.04% |
| 2021 Q3 | 3.15 Billion USD | 321.63% |
| 2021 Q4 | 4.02 Billion USD | 27.39% |
| 2021 Q1 | 3.52 Billion USD | 9702.78% |
| 2020 FY | 4.61 Billion USD | -41.44% |
| 2020 Q3 | 2.29 Billion USD | 410.43% |
| 2020 Q4 | 36 Million USD | -98.43% |
| 2020 Q1 | 2.99 Billion USD | 7.46% |
| 2020 Q2 | -738 Million USD | -124.63% |
| 2019 Q4 | 2.78 Billion USD | 48.77% |
| 2019 Q2 | 733 Million USD | -70.01% |
| 2019 FY | 7.88 Billion USD | 38.6% |
| 2019 Q1 | 2.44 Billion USD | 233.84% |
| 2019 Q3 | 1.87 Billion USD | 155.66% |
| 2018 Q1 | 2.77 Billion USD | 5228.85% |
| 2018 Q2 | 1.97 Billion USD | -28.8% |
| 2018 FY | 5.68 Billion USD | 7.12% |
| 2018 Q3 | 2.73 Billion USD | 38.62% |
| 2018 Q4 | -1.82 Billion USD | -166.76% |
| 2017 Q3 | 1.62 Billion USD | -14.85% |
| 2017 FY | 5.3 Billion USD | -10.82% |
| 2017 Q4 | 52 Million USD | -96.8% |
| 2017 Q1 | 1.7 Billion USD | 22.98% |
| 2017 Q2 | 1.9 Billion USD | 11.99% |
| 2016 Q1 | 1.34 Billion USD | -11.21% |
| 2016 FY | 5.95 Billion USD | 15.73% |
| 2016 Q3 | 1.59 Billion USD | -0.75% |
| 2016 Q2 | 1.6 Billion USD | 18.93% |
| 2016 Q4 | 1.38 Billion USD | -12.96% |
| 2015 Q3 | 1.23 Billion USD | -9.81% |
| 2015 Q2 | 1.36 Billion USD | 33.66% |
| 2015 Q1 | 1.02 Billion USD | 226.17% |
| 2015 Q4 | 1.51 Billion USD | 23.13% |
| 2015 FY | 5.14 Billion USD | 189.97% |
| 2014 Q1 | 980 Million USD | -13.12% |
| 2014 Q3 | 506 Million USD | -53.92% |
| 2014 Q4 | -810 Million USD | -260.08% |
| 2014 FY | 1.77 Billion USD | -57.03% |
| 2014 Q2 | 1.09 Billion USD | 12.04% |
| 2013 Q1 | 968 Million USD | -37.13% |
| 2013 Q2 | 1.06 Billion USD | 10.33% |
| 2013 Q3 | 964 Million USD | -9.74% |
| 2013 Q4 | 1.12 Billion USD | 17.01% |
| 2013 FY | 4.12 Billion USD | -21.74% |
| 2012 Q3 | 1.58 Billion USD | 25.1% |
| 2012 FY | 5.27 Billion USD | 53.65% |
| 2012 Q4 | 1.53 Billion USD | -2.86% |
| 2012 Q1 | 883 Million USD | -23.72% |
| 2012 Q2 | 1.26 Billion USD | 43.49% |
| 2011 Q4 | 1.15 Billion USD | 9284.38% |
| 2011 Q3 | 12.33 Million USD | -99.2% |
| 2011 Q2 | 1.54 Billion USD | 112.95% |
| 2011 Q1 | 723.19 Million USD | 0.0% |
| 2011 FY | 3.43 Billion USD | -17.83% |
| 2010 FY | 4.17 Billion USD | -9.89% |
| 2009 FY | 4.63 Billion USD | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Bayer Aktiengesellschaft | -2.94 Billion EUR | 265.352% |
| Sanofi | 5.4 Billion EUR | 9.944% |